Mayo Clinic Proceedings Home

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma


      Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program to reduce day-100 all-cause mortality. Currently our mortality has been reduced to 0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater. Outpatient transplantation is safe and reduces patient-incurred costs.

      Abbreviations and Acronyms:

      ASCT (autologous stem cell transplant), MEL (melphalan), MM (multiple myeloma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McElwain T.J.
        • Powles R.L.
        High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
        Lancet. 1983; 2: 822-824
        • Attal M.
        • Lauwers-Cances V.
        • Hulin C.
        • et al.
        • IFM 2009 Study
        Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.
        N Engl J Med. 2017; 376: 1311-1320
        • Attal M.
        • Harousseau J.L.
        • Facon T.
        • et al.
        • InterGroupe Francophone du Myélome
        Single versus double autologous stem-cell transplantation for multiple myeloma.
        N Engl J Med. 2003; 349: 2495-2502
        • Child J.A.
        • Morgan G.J.
        • Davies F.E.
        • et al.
        • Medical Research Council Adult Leukaemia Working Party
        High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
        N Engl J Med. 2003; 348: 1875-1883
      1. Medical education in the United States. Introduction.
        JAMA. 1969; 210: 1455-1456
        • Belete H.
        • Burns L.J.
        • Shanley R.
        • et al.
        Transplantation-related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.
        Am J Hematol. 2017; 92: E529-E533
        • Sanchez L.
        • Sylvester M.
        • Parrondo R.
        • Mariotti V.
        • Eloy J.A.
        • Chang V.T.
        In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study.
        Biol Blood Marrow Transplant. 2017; 23: 1203-1207
        • Gaballa M.R.
        • Laubach J.P.
        • Schlossman R.L.
        • et al.
        Management of myeloma-associated renal dysfunction in the era of novel therapies.
        Expert Rev Hematol. 2012; 5 (quiz 67-68): 51-66